Menu
Montecito
Pac Premier
Giving Guide
Loading...
You are here:  Home  >  'FDA'  -  Page 8
Latest

FDA approves Amgen’s Parsabiv drug to treat chronic kidney disease

By   /  Tuesday, February 7th, 2017  /  Central Coast Health Watch, Latest news  /  Comments Off on FDA approves Amgen’s Parsabiv drug to treat chronic kidney disease

The U.S. Food and Drug Administration approved Amgen’s Parsabiv drug to treat patients with chronic kidney disease, the company announced on Feb. 7. The Thousand Oaks-based biotech company’s Parsabiv is the first therapy approved for the treatment of secondary hyperparathyroidism for patients on hemodialysis in 12 years, Amgen said. “We are excited about today’s approval Read More →

Read More →
Latest

Sientra settles lawsuits over public offering

By   /  Friday, November 4th, 2016  /  Central Coast Health Watch, Latest news, Technology  /  Comments Off on Sientra settles lawsuits over public offering

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Amgen leukemia drug cures 39 percent of treated patients, study finds

By   /  Tuesday, October 4th, 2016  /  Central Coast Health Watch, Latest news  /  Comments Off on Amgen leukemia drug cures 39 percent of treated patients, study finds

Amgen’s new leukemia drug cured 39 percent of pediatric patients who received treatment, the Thousand Oaks company said Oct. 3 after publishing results of a new study in the Journal of Clinical Oncology. Blincyto, which treats a rare form of the disease known as precursor B-cell acute lymphoblastic leukemia, sent 27 patients out of 70 Read More →

Read More →
Latest

FDA gives big win to Amgen in biosimilars race

By   /  Friday, September 30th, 2016  /  Central Coast Health Watch, East Ventura County, Latest news  /  Comments Off on FDA gives big win to Amgen in biosimilars race

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

FDA approves Amgen biosimilar of AbbVie’s Humira

By   /  Friday, September 23rd, 2016  /  Central Coast Health Watch, East Ventura County, Latest news  /  Comments Off on FDA approves Amgen biosimilar of AbbVie’s Humira

The Food and Drug Administration approved Amgen’s Humira biosimilar Sept. 23. Amjevita, formerly known as ABP 501 and made by Thousand Oaks-biotech giant Amgen, replicates the effects of Humira, which is approved to treat nine conditions including rheumatoid arthritis, skin disorders and colon inflammation. Humira, made by Chicago-based competitor AbbVie, typically costs $20,000 per year Read More →

Read More →
Latest

Sientra finds new factory to make breast implants

By   /  Friday, August 12th, 2016  /  Central Coast Health Watch, middle, Technology  /  Comments Off on Sientra finds new factory to make breast implants

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Read More →
Latest

Abbvie sues Amgen to block sales of Humira biosimilar

By   /  Friday, August 5th, 2016  /  Central Coast Health Watch, Latest news, Law, Technology  /  Comments Off on Abbvie sues Amgen to block sales of Humira biosimilar

Thousand Oaks-based biotech giant Amgen faces a lawsuit seeking to block it from selling a biosimilar of AbbVie’s popular Humira. The rheumatoid arthritis medicine is Abbvie’s best seller. Sales were up 17 percent in the second quarter to $4.15 billion and accounted for 61 percent of AbbVie’s 2015 revenue. Abbvie claims Amgen’s proposed copy would Read More →

Read More →